-+ 0.00%
-+ 0.00%
-+ 0.00%

Moberg Pharma (STO:MOB) Is In A Strong Position To Grow Its Business

Simply Wall St·11/21/2026 08:07:28
Listen to the news

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.

So should Moberg Pharma (STO:MOB) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. First, we'll determine its cash runway by comparing its cash burn with its cash reserves.

How Long Is Moberg Pharma's Cash Runway?

A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. In September 2026, Moberg Pharma had kr205m in cash, and was debt-free. Looking at the last year, the company burnt through kr31m. So it had a cash runway of about 6.6 years from September 2026. While this is only one measure of its cash burn situation, it certainly gives us the impression that holders have nothing to worry about. Depicted below, you can see how its cash holdings have changed over time.

debt-equity-history-analysis
OM:MOB Debt to Equity History November 21st 2026

Check out our latest analysis for Moberg Pharma

How Well Is Moberg Pharma Growing?

Moberg Pharma managed to reduce its cash burn by 56% over the last twelve months, which suggests it's on the right flight path. And revenue is up 48% in that same period; also a good sign. Overall, we'd say its growth is rather impressive. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years.

How Hard Would It Be For Moberg Pharma To Raise More Cash For Growth?

While Moberg Pharma seems to be in a decent position, we reckon it is still worth thinking about how easily it could raise more cash, if that proved desirable. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.

Moberg Pharma has a market capitalisation of kr453m and burnt through kr31m last year, which is 6.9% of the company's market value. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan.

How Risky Is Moberg Pharma's Cash Burn Situation?

It may already be apparent to you that we're relatively comfortable with the way Moberg Pharma is burning through its cash. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. And even its cash burn relative to its market cap was very encouraging. Taking all the factors in this report into account, we're not at all worried about its cash burn, as the business appears well capitalized to spend as needs be. Taking an in-depth view of risks, we've identified 3 warning signs for Moberg Pharma that you should be aware of before investing.

Of course Moberg Pharma may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.